

Ref. No: 0583
Date: 12/01/24
Subject: Biologic Medicines (Dermatology)

REQUEST

1. How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilar
- Apremilast
- Bimekizumab
- Brodalumab
- Certolizumab
- Deucravacitinib
- Dimethyl fumarate
- Etanercept - Enbrel
- Etanercept Biosimilar
- Guselkumab
- Infliximab - Remicade
- Infliximab Biosimilar
- Ixekizumab
- Risankizumab
- Secukinumab
- Tildrakizumab
- Ustekinumab

RESPONSE

St Helens and Knowsley Teaching Hospitals NHS Trust and Southport and Ormskirk Hospital NHS Trust became a single legal entity known as Mersey and West Lancashire Teaching Hospitals NHS Trust on 1st July 2023, as such parts of the response may be provided in two sections relating to the hospital sites of each of the legacy organisations.

1. How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

Treatment	No. Patients
Adalimumab - Humira	12
Adalimumab Biosimilar	111
Apremilast	71
Bimekizumab	0
Brodalumab	0
Certolizumab	<5
Deucravacitinib	0
Dimethyl fumarate	<5

Etanercept - Enbrel	<5
Etanercept Biosimilar	0
Guselkumab	18
Infliximab - Remicade	0
Infliximab Biosimilar	0
Ixekizumab	15
Risankizumab	26
Secukinumab	17
Tildrakizumab	0
Ustekinumab	30

Section 40: personal information

We are unable to provide precise figures when those figures refer to individuals in volumes of 5 or less due to the risk that individuals will be re-identified, as we are required to protect their identity under the General Data Protection Regulations & Data Protection Act 2018. In such circumstances Section 40(2) and Section 40(3) of the Freedom of Information Act apply. In this case, our view is that disclosure would breach the first data protection principle which states that personal data should be processed “lawfully, fairly and in a transparent manner”. It is the lawful aspect of this principle which, in our view, would be breached by disclosure, and in such circumstances, Section 40 confers an absolute exemption on disclosure.